Immunotherapy drug shows promise for tough brain cancers

NCT ID NCT03557359

Completed Disease control Sponsor: Fabio Iwamoto, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 35 adults with recurrent or progressive IDH mutant gliomas that had been previously treated with alkylating agents. The main goal was to see if the drug could shrink tumors. The study is now complete, and results will show how many patients responded to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo)
What this could lead to: If successful, this could point toward a new treatment option for people with recurrent IDH mutant gliomas that have stopped responding to standard chemotherapy.
What could go wrong: This is a small, early-phase trial with only 35 participants and no comparison group, so results may not be definitive. Nivolumab can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMAS

Contacts and locations

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Miami Cancer Center

Miami, Florida, 33176, United States
Weill Cornell Medical College

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.